UCB (OTCMKTS:UCBJF) Stock Price Passes Above Fifty Day Moving Average – Should You Sell?

UCB SA (OTCMKTS:UCBJFGet Free Report)’s share price passed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $192.24 and traded as high as $194.91. UCB shares last traded at $194.90, with a volume of 1,000 shares changing hands.

UCB Trading Up 1.6 %

The firm has a fifty day moving average of $192.24 and a 200-day moving average of $185.83. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.

About UCB

(Get Free Report)

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

See Also

Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.